Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Retacrit [legacy through FY23] by Year
Retacrit (epoetin alfa biosimilar) [legacy through FY23] — Worldwide operational (constant-currency) YoY (%) (%)
Pfizer Retacrit [legacy through FY23]: -1.0% in FY2023, up 7.0 pts from a year earlier. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
“|| Retacrit | 80 | 79 | 1% | (1%) | — | — | — | — | 1 | 3 | (43%) | (44%)”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Reported in Form 8-K Revenue Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Retacrit (epoetin alfa biosimilar) [legacy through FY23] — Worldwide operational (constant-currency) YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | -1.0% | +7.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
| FY2022 | Dec 31, 2022 | -8.0% | -2.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗ |
| FY2021 | Dec 31, 2021 | -6.0% | -23.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗ |
| FY2020 | Dec 31, 2020 | 17.0% | -8.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312020xex99.htm, filed 2021-02-02) ↗ |
| FY2019 | Dec 31, 2019 | 25.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312019xex99.htm, filed 2020-01-28) ↗ |
Cite this data
StockData. (2026). Pfizer Retacrit [legacy through FY23] (%), annual FY2019–FY2023 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/retacrit-leg-oper-ww
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.